Symptom Reduction

treatment gains

Symptom reduction occupies a contested position within the depth-psychology corpus, functioning simultaneously as a primary treatment goal, a secondary outcome measure, and—from the more analytically rigorous standpoints—a philosophically insufficient terminus for genuine therapeutic work. The empirical literature, represented here by Abbass, de Maat, and Chambless, treats symptom reduction as a quantifiable index of treatment efficacy, marshalling effect sizes and standardized mean differences to demonstrate that short-term psychodynamic and long-term psychoanalytic therapies produce statistically robust symptom amelioration. Yet de Maat’s careful bifurcation of ‘symptom reduction’ from ‘personality change’ as discrete outcome categories reveals the structural tension embedded in this discourse: analytic traditions insist that symptomatic relief divorced from structural characterological transformation is incomplete, even illusory. This tension reappears in Flores’s typology of focused-criteria groups, where symptom reduction defines an entire therapeutic modality distinct from deeper relational work. The addiction and pharmacological literature—Blum, Miller, Bettmann—operationalizes symptom reduction through scaled instruments such as the CASS and Y-OQ, examining how sobriety, craving, and affective dysregulation respond to intervention. Shapiro’s EMDR studies extend this to post-traumatic presentations. Across these traditions, a persistent question persists: whether symptom reduction constitutes an end, a means, or a marker for processes that matter more deeply.

In the library

Effect Sizes and Success Rates for Symptom Reduction and Personality Change… Symptoms 1.03 (n = 6) 59%… Personality 0.54 (n = 7) 59%

De Maat formally distinguishes symptom reduction from personality change as separable outcome categories, demonstrating that psychoanalytic therapy yields larger effect sizes for symptom relief than for personality restructuring, thereby indexing the gap between surface and structural change.

de Maat, Saskia, The Effectiveness of Long-Term Psychoanalytic Therapy: A Systematic Review of Empirical Studies, 2009thesis

Dig deeper with Sebastian →

Benefits were observed across a broad range of outcome measures including general measures and somatic symptoms, as well as depression, anxiety, interpersonal and social adjustment… suggesting behavioural as well as symptomatic gains.

Abbass establishes that short-term psychodynamic psychotherapy produces modest to large symptomatic gains across multiple diagnostic categories, with effect sizes that increase rather than decay at long-term follow-up.

Abbass, Allan A, Short-term psychodynamic psychotherapies for common mental disorders, 2014thesis

Dig deeper with Sebastian →

1.1 Reduction in general psychiatric symptoms: short-term -0.49 (-0.72 to -0.27)… 1.2 Reduction in general psychiatric symptoms: medium-term -0.09 (-0.34 to 0.15)

Abbass’s subgroup analyses reveal that the magnitude of psychiatric symptom reduction in STPP is substantial in the short term but attenuates across diagnostic subgroups and follow-up intervals, complicating claims of uniformly durable gains.

Abbass, Allan A, Short-term psychodynamic psychotherapies for common mental disorders, 2014thesis

Dig deeper with Sebastian →

focused change groups are specifically designed to change, alter, or eliminate a group member’s self-destructive or self-defeating target behavior… when the focus is on symptom reduction (shyness, grief, panic disorders, divorce recovery, pain management)

Flores positions symptom reduction as the defining therapeutic objective of a specific modality—focused-criteria groups—thereby marking it as an approach distinct from, and subordinate to, deeper characterological work within the group psychotherapy tradition.

Flores, Philip J, Group Psychotherapy with Addicted Populations An, 1997thesis

Dig deeper with Sebastian →

the most recent review of psychodynamic therapies in specific disorders… found significantly increased gains in follow-up compared with immediately post treatment in a group of 46 studies

Abbass situates STPP’s symptomatic gains within a broader meta-analytic consensus showing that treatment-gains in psychodynamic therapy do not diminish post-termination but continue to grow, challenging the pharmacotherapy assumption that psychological treatments offer less durable relief.

Abbass, Allan A, Short-term psychodynamic psychotherapies for common mental disorders, 2014supporting

Dig deeper with Sebastian →

How Substance Abuse Recovery Skills, Readiness to Change and Symptom Reduction Impact Change Processes in Wilderness Therapy Participants… Analysis of the complete data sets of 41 adolescents indicated that client Y-OQ scores improved significantly at post and follow-up assessments.

Bettmann frames symptom reduction as an investigable process variable within wilderness therapy, examining it in relation to motivational readiness and substance-abuse coping skills rather than treating it as a self-evident endpoint.

Bettmann, Joanna Ellen, How Substance Abuse Recovery Skills, Readiness to Change and Symptom Reduction Impact Change Processes in Wilderness Therapy Participants, 2013thesis

Dig deeper with Sebastian →

explored which processes impact that symptom reduction… The present study sought to explore the impact of motivation to change and substance abuse recovery skills on symptom reduction among adolescent WT participants.

Bettmann argues that symptom reduction in adolescent therapeutic contexts is not a primary target but an outcome mediated by motivational and coping-strategy processes, demanding that clinicians attend to mechanism rather than magnitude.

Bettmann, Joanna Ellen, How Substance Abuse Recovery Skills, Readiness to Change and Symptom Reduction Impact Change Processes in Wilderness Therapy Participants, 2013supporting

Dig deeper with Sebastian →

Our pilot experiment found a significant reduction of chronic symptoms, measured by the Chronic Abstinence Symptom Severity (CASS) Scale. The combined group (IV and oral) did significantly better than the oral-only group over the first week and 30-day follow-up period.

Miller and Blum operationalize symptom reduction in substance-use disorder through the CASS instrument, demonstrating that neuroadaptagen amino-acid therapy produces statistically significant multi-domain symptomatic improvement, situating the concept within a neurobiological rather than purely psychological framework.

Miller, Merlene, Early Intervention of Intravenous KB220IV-Neuroadaptagen Amino-Acid Therapy (NAAT)™ Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study, 2012supporting

Dig deeper with Sebastian →

Our pilot experiment found a significant reduction of chronic symptoms, measured by the Chronic Abstinence Symptom Severity (CASS) Scale… significant declines (p =.00001) from pre- to post-treatment: t = 19.1 for Emotion, t = 16.1 for Somatic, and t = 14.9 for Impaired Cognition.

Blum reports statistically dramatic multi-domain symptom reduction from neuroadaptagen therapy, underscoring that in addiction psychiatry symptom reduction is framed primarily as a biological rather than psychological achievement.

Blum, Kenneth, Early Intervention of Intravenous KB220IV Neuroadaptagen Amino-Acid Therapy (NAAT)™ Improves Behavioral Outcomes in a Residential Addiction Treatment Program: A Pilot Study, 2012supporting

Dig deeper with Sebastian →

After three sessions of EMDR, 56% of the children no longer met PTSD diagnostic criteria and clinical improvements were reported on inventories of posttraumatic reactions, anxiety, and depression. These changes remained stable at a 6-month follow-up.

Shapiro presents EMDR-induced symptom reduction in trauma-exposed children as both diagnostically and clinically significant, with symptomatic remission serving as the primary evidence of treatment validity rather than an incidental byproduct of deeper processing.

Shapiro, Francine, Eye Movement Desensitization and Reprocessing (EMDR): Basic Principles, Protocols, and Procedures, 2001supporting

Dig deeper with Sebastian →

Psychological treatments have long been presumed to have more stable effects than pharmacotherapy, either because they redress underlying propensities that contribute to risk or because patients acquire stable skills that enable them to cope better with those underlying vulnerabilities.

Chambless and Hollon argue that symptom reduction achieved through psychological treatment is qualitatively distinct from pharmacological relief because it may address generative vulnerability structures rather than merely suppressing symptomatic expression.

Chambless, Dianne L., Defining Empirically Supported Therapies, 1998supporting

Dig deeper with Sebastian →

results in severe pathology should be interpreted cautiously, as they are based on only three studies… These ESs are likely to be highly correlated since they present dimensions from only two separate instruments.

De Maat cautions that symptom-reduction effect sizes in long-term psychoanalytic therapy for severe pathology are methodologically fragile, dependent on small samples and correlated instruments, qualifying the otherwise positive review findings.

de Maat, Saskia, The Effectiveness of Long-Term Psychoanalytic Therapy: A Systematic Review of Empirical Studies, 2009supporting

Dig deeper with Sebastian →

Summarised self-reported symptoms and symptom reduction… Improved ADHD symptoms, Mood stabilisation, Reduced irritability, Less exhaustion

De Jong employs symptom reduction as the primary patient-reported metric for evaluating premenstrual psychostimulant dose adjustment in ADHD, illustrating that the concept serves as both a clinical target and a patient-centred outcome measure across pharmacological contexts.

de Jong, M., Female-specific pharmacotherapy in ADHD: premenstrual adjustment of psychostimulant dosage, 2023supporting

Dig deeper with Sebastian →

Males showed a significant increase in stress from post to follow-up, coupled with significant reduction in depressive symptoms. No significant differences were found between post and the follow-up in anxiety for males.

Russell’s longitudinal data from wilderness therapy reveal that symptom reduction is domain-specific and gender-differentiated, cautioning against global claims about treatment-gains and highlighting the importance of disaggregated outcome monitoring.

Russell, Keith C., Adolescent Substance-use Treatment: Service Delivery, Research on Effectiveness, and Emerging Treatment Alternatives, 2008supporting

Dig deeper with Sebastian →

If it can alleviate symptoms long enough for patients to reassess their goals, then that is fine. One danger is, however, that it may become an object of barter and dissension between patients and therapists.

Addenbrooke treats pharmacologically mediated symptom reduction in heroin addiction as instrumentally valuable but potentially relationship-distorting, warning that it can become a site of therapeutic impasse rather than a foundation for deeper recovery work.

Addenbrooke, Mary, Survivors of Addiction: Narratives of Recovery, 2011aside

Dig deeper with Sebastian →

Related terms